ASCO 2023 | Where are we in sequencing ADCs in HR+ breast cancer?

Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, comments on the best sequence of antibody-drug conjugates for HR+ breast cancer. Trastuzumab deruxtecan and sacituzumab govitecan are two ADCs currently approved for HR+ breast cancer. Whilst the former was assessed in the DESTINY-Breast04 trial (NCT03734029) in patients who were only treated with one or two prior lines of therapy, the latter was assessed in more heavily pretreated patients in the Phase III TROPiCS-02 study (NCT03901339). Trastuzumab deruxtecan is, therefore, recommended first in patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.